<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 16 Jun 2021 13:22:38 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>一篇搞懂基因疗法</title><link>https://mp.weixin.qq.com/s/dQl2ISGNGyzg1HD7QLEagA</link><description></description><content:encoded><![CDATA[一篇搞懂基因疗法]]></content:encoded><pubDate>Wed, 16 Jun 2021 12:54:55 +0800</pubDate></item><item><title>千家初创Biotech迎福利！Cytiva重磅开启Think Big 2.0笃行思远双选平台项目</title><link>https://mp.weixin.qq.com/s/XdJy9puoBLes6dgkRwL3Cw</link><description></description><content:encoded><![CDATA[千家初创Biotech迎福利！Cytiva重磅开启Think Big 2.0笃行思远双选平台项目]]></content:encoded><pubDate>Wed, 16 Jun 2021 12:54:55 +0800</pubDate></item><item><title>2019至2021年，肿瘤细胞治疗的研发状况</title><link>https://mp.weixin.qq.com/s/9MrSgFPVCbfOld0ysmKXOw</link><description></description><content:encoded><![CDATA[2019至2021年，肿瘤细胞治疗的研发状况]]></content:encoded><pubDate>Wed, 16 Jun 2021 12:54:55 +0800</pubDate></item><item><title>Novavax新冠三聚体蛋白疫苗媲美mRNA疫苗，三叶草生物在路上</title><link>https://mp.weixin.qq.com/s/0jKm9fIrsVJWB_U0YdSisw</link><description></description><content:encoded><![CDATA[Novavax新冠三聚体蛋白疫苗媲美mRNA疫苗，三叶草生物在路上]]></content:encoded><pubDate>Wed, 16 Jun 2021 12:54:55 +0800</pubDate></item><item><title>CAR-T在肿瘤微环境中面临哪些挑战？</title><link>https://mp.weixin.qq.com/s/hQHBor9lVVPwikGhZ5M6Sw</link><description></description><content:encoded><![CDATA[CAR-T在肿瘤微环境中面临哪些挑战？]]></content:encoded><pubDate>Tue, 15 Jun 2021 11:35:57 +0800</pubDate></item><item><title>【今晚19:00】大咖讲座：如何做好生物制品关键属性质量监控？</title><link>https://mp.weixin.qq.com/s/Dj9exIYCrvkhm3XjXHvzVg</link><description></description><content:encoded><![CDATA[【今晚19:00】大咖讲座：如何做好生物制品关键属性质量监控？]]></content:encoded><pubDate>Tue, 15 Jun 2021 11:35:57 +0800</pubDate></item><item><title>首款胶质瘤溶瘤病毒产品获批，国内多家企业布局</title><link>https://mp.weixin.qq.com/s/aRU2Ymmc7LZL4COhkdUOSQ</link><description></description><content:encoded><![CDATA[首款胶质瘤溶瘤病毒产品获批，国内多家企业布局]]></content:encoded><pubDate>Tue, 15 Jun 2021 11:35:57 +0800</pubDate></item><item><title>8亿美元打水漂？Biogen眼科基因疗法Ⅲ期临床失败</title><link>https://mp.weixin.qq.com/s/oHurVQRgT6qCoYv-E1cYyw</link><description></description><content:encoded><![CDATA[8亿美元打水漂？Biogen眼科基因疗法Ⅲ期临床失败]]></content:encoded><pubDate>Tue, 15 Jun 2021 11:35:57 +0800</pubDate></item><item><title>21亿美元：葛兰素史克从iTeos引进TIGIT抗体</title><link>https://mp.weixin.qq.com/s/PKA4s29FWj6eOMUL3gmB8A</link><description></description><content:encoded><![CDATA[21亿美元：葛兰素史克从iTeos引进TIGIT抗体]]></content:encoded><pubDate>Tue, 15 Jun 2021 11:35:57 +0800</pubDate></item><item><title>ASCO上的中国之声|来自君实、恒瑞、亚盛……</title><link>https://mp.weixin.qq.com/s/LZe-HSZvKtdob4IVItwyKA</link><description></description><content:encoded><![CDATA[ASCO上的中国之声|来自君实、恒瑞、亚盛……]]></content:encoded><pubDate>Mon, 14 Jun 2021 12:13:55 +0800</pubDate></item><item><title>邀请函丨苏州驾玉生物四周年庆典暨实验室开幕仪式</title><link>https://mp.weixin.qq.com/s/pgYDZBZNjtftYN2NCxYKVg</link><description></description><content:encoded><![CDATA[邀请函丨苏州驾玉生物四周年庆典暨实验室开幕仪式]]></content:encoded><pubDate>Mon, 14 Jun 2021 12:13:55 +0800</pubDate></item><item><title>靶点药讯64|首个国产ADC，荣昌生物HER2-ADC获批上市​、第四代EGFR靶向疗法，福沃药业首个1类新药在中国获批临床</title><link>https://mp.weixin.qq.com/s/Ok-MuxqqyyLgM2Vy9Wr55w</link><description></description><content:encoded><![CDATA[靶点药讯64|首个国产ADC，荣昌生物HER2-ADC获批上市​、第四代EGFR靶向疗法，福沃药业首个1类新药在中国获批临床]]></content:encoded><pubDate>Sun, 13 Jun 2021 08:33:32 +0800</pubDate></item><item><title>嘉宾发布！2021中国（苏州）抗体药物、细胞和基因治疗峰会邀您共赴行业盛会！</title><link>https://mp.weixin.qq.com/s/A5riZTibi6ONWnuL10PIDg</link><description></description><content:encoded><![CDATA[嘉宾发布！2021中国（苏州）抗体药物、细胞和基因治疗峰会邀您共赴行业盛会！]]></content:encoded><pubDate>Sun, 13 Jun 2021 08:33:32 +0800</pubDate></item><item><title>2021 ASCO|Day2-3，重磅研究汇总</title><link>https://mp.weixin.qq.com/s/zOYpSsRTqILM32jYCDJ6iA</link><description></description><content:encoded><![CDATA[2021 ASCO|Day2-3，重磅研究汇总]]></content:encoded><pubDate>Sat, 12 Jun 2021 11:58:31 +0800</pubDate></item><item><title>生物药欧美注册申报，是挑战也是机会</title><link>https://mp.weixin.qq.com/s/4jsT8A-9fvRy07AsLIcYow</link><description></description><content:encoded><![CDATA[生物药欧美注册申报，是挑战也是机会]]></content:encoded><pubDate>Sat, 12 Jun 2021 11:58:31 +0800</pubDate></item><item><title>专访丨沈栋博士：mRNA笃思慎行三十载，落地春雷掷有声</title><link>https://mp.weixin.qq.com/s/hfalSgIRUtCcUm0pJ6M5Ug</link><description></description><content:encoded><![CDATA[专访丨沈栋博士：mRNA笃思慎行三十载，落地春雷掷有声]]></content:encoded><pubDate>Fri, 11 Jun 2021 10:04:44 +0800</pubDate></item><item><title>聚智聚力，同心同行 | SAPA2021中国年会即将隆重开幕！</title><link>https://mp.weixin.qq.com/s/ekGhpP5QWSjwNtAyEFvB5A</link><description></description><content:encoded><![CDATA[聚智聚力，同心同行 | SAPA2021中国年会即将隆重开幕！]]></content:encoded><pubDate>Fri, 11 Jun 2021 10:04:44 +0800</pubDate></item><item><title>蓝鸟Zynteglo解封</title><link>https://mp.weixin.qq.com/s/cVEcIZ2tVVts_6qerv2icQ</link><description></description><content:encoded><![CDATA[蓝鸟Zynteglo解封]]></content:encoded><pubDate>Fri, 11 Jun 2021 10:04:44 +0800</pubDate></item><item><title>mRNA药物专栏丨mRNA不止于斯</title><link>https://mp.weixin.qq.com/s/IaDYuRMHyNS6M0c33pYDWw</link><description></description><content:encoded><![CDATA[mRNA药物专栏丨mRNA不止于斯]]></content:encoded><pubDate>Thu, 10 Jun 2021 11:36:05 +0800</pubDate></item><item><title>FDA批准AD新药Aducanumab惹争议</title><link>https://mp.weixin.qq.com/s/Ses2NLeo9SapOtcU9nZm5g</link><description></description><content:encoded><![CDATA[FDA批准AD新药Aducanumab惹争议]]></content:encoded><pubDate>Thu, 10 Jun 2021 11:36:05 +0800</pubDate></item></channel></rss>